Shaun Ross
Pediatrics · Poplar Bluff, MONPI 1740268333
Payments from drug & device makers
Across 181 payments — averaging $12.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Neurocrine Biosciences, Inc.$221
- Dexcom, Inc.$217
- Lilly USA, LLC$178
- Insulet Corporation$121
- Bayer$78
- plus $321 from 10 others
What the payments were for
- Food & beverage$2,308100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 121 | $1,173 |
| Neurocrine Biosciences, Inc. | 9 | $221 |
| Dexcom, Inc. | 16 | $217 |
| Lilly USA, LLC | 8 | $178 |
| Insulet Corporation | 6 | $121 |
| Bayer | 4 | $78 |
| Sanofi Pasteur Inc. | 2 | $57 |
| Abbott | 3 | $56 |
| AstraZeneca | 2 | $42 |
| Antares Pharma, Inc. | 2 | $37 |
| Tandem Diabetes Care, Inc. | 3 | $35 |
| AbbVie | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Averitas Pharma Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,308 in reported general payments places this provider in the 90th percentile of 1,306 pediatrics providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 307 | $333,874 |
| MounjaroTirzepatide | 112 | $127,005 |
| JardianceEmpagliflozin | 177 | $126,549 |
| TrulicityDulaglutide | 78 | $73,986 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 85 | $73,447 |
| JanuviaSitagliptin Phosphate | 86 | $72,065 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $53,375 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $37,554 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 110 | $36,814 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 217 | $36,557 |
| RybelsusSemaglutide | 18 | $23,374 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $22,399 |
| VascepaIcosapent Ethyl | 46 | $21,329 |
| FarxigaDapagliflozin Propanediol | 29 | $20,867 |
| LyumjevInsulin Lispro-Aabc | 12 | $20,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,173 | $359,042337 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog, Insulin Lispro | $178 | $232,589262 claims |
| AstraZenecaFarxiga | $42 | $20,86729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,306 pediatrics providers in Missouri.
Other pediatrics in Poplar Bluff
- Kathleen DoisyColumbia$70.4M
- Nadine MokhallatiKansas City$10.2M
- Jennifer DiltsKansas City$517K
- Abbey MasonbrinkKansas City$505K
- Craig SpiegelBridgeton$494K
- Amanda NedvedKansas City$201K
- Jennifer HeithausSaint Louis$182K
- Alexander FaySaint Louis$118K
- Jennifer GoldmanKansas City$114K
- David GoldsteinColumbia$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.